Form 4: Sensei Biotherapeutics Director, Jessie English, Acquires 19,000 Stock Options

Director Jessie English acquired 19,000 stock options in Sensei Biotherapeutics, Inc. on June 11, 2024, at an exercise price of $0.709.

Summary

• Jessie English, a director of Sensei Biotherapeutics, Inc., acquired 19,000 stock options on June 11, 2024.
• The exercise price of these options is $0.709.
• The options vest in 12 equal monthly installments over one year, becoming fully vested on June 11, 2025, contingent upon continuous service with the Issuer.
• The options will be fully vested on the date of the Company's next annual stockholder meeting, subject to continuous service with the Issuer through such vesting date.
• The expiration date for the options is June 10, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's acquisition could be seen as a positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, Sensei Biotherapeutics, director, beneficial ownership, Form 4, SNSE, Jessie English